LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage biopharmaceutical company focused on developing therapies targeting lipid signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the company’s board of directors .
“We are delighted to welcome Tamara to the Artelo Board of Directors,” said Connie Matsui, Chairman of the Board. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience in supporting biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe that his guidance and insight will be instrumental in the development and growth of the company.
Ms. Seymour is a corporate finance veteran with three decades of experience in the biotechnology and life sciences industries. She has held the position of CFO in public and private companies funded by venture capital at all stages of their development. Ms. Seymour’s background includes finance leadership, investor relations, managed care and reimbursement, human resources, administration and information technology. She has raised over $ 250 million in multiple private and public equity and debt financings, including leading an IPO.
“Now is an exciting time to join Artelo as she envisions several strategies to advance and accelerate her non-clinical and clinical stage programs,” added Ms. Seymour. “I look forward to working with the very capable team to further realize Artelo’s potential.
In addition to her experience as an executive in public companies, Ms. Seymour was also a member of the board of directors and chair of the audit committee of Beacon Discovery, Inc., a drug discovery company in San Diego, California. California, which was recently acquired. by Eurofins Scientifique. Ms. Seymour is a Certified Public Accountant (inactive). She received an MBA, majoring in finance, from Georgia State University and earned her BBA, majoring in accounting, from Valdosta State University.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapies targeting lipid signaling pathways, including the endocannabinoid system. Artelo is rapidly developing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies cutting-edge scientific, regulatory and business discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the development of the Company’s products, clinical and regulatory timelines, market opportunities, competitive position, possible or expected future operating results, business strategies, potential growth opportunities and other statements of a predictive nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections regarding the industry and markets in which we operate and on the current beliefs and assumptions of management. These statements can be identified by the use of forward-looking phrases, including, but not limited to, “expect”, “anticipate”, “intend”, “plan”, “believe” , “Estimate”, “predict”, “project”, “should”, “would” and similar expressions and the negative aspects of these terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any results, performance or future achievements expressed or implied by the future. staring statements. These factors include those set forth in documents filed by the Company with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Phone. : 212-671-1020
E-mail: [email protected]